Drug intelligence / Profile preview

Sorbiline

Development stage: Unknown
Lead developer: Franco-Indian Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Sorbiline is an oral combination medication developed and marketed by Franco-Indian Pharmaceuticals for the treatment of liver and digestive disorders. It contains sorbitol, which acts as an osmotic laxative to relieve constipation and stimulate bile flow, and tricholine citrate, a lipotropic agent that facilitates fat metabolism in the liver and helps reduce cholesterol levels. The syrup is primarily indicated for fatty liver disease, hepatotoxicity, and chronic constipation, supporting overall hepatic function and regular bowel movements.

Brand names: Sorbiline

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on Sorbiline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sorbiline.

Explore the full profile